These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 1380229)

  • 21. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
    Baba M; Tanaka H; De Clercq E; Pauwels R; Balzarini J; Schols D; Nakashima H; Perno CF; Walker RT; Miyasaka T
    Biochem Biophys Res Commun; 1989 Dec; 165(3):1375-81. PubMed ID: 2575380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
    Kavlick MF; Shirasaka T; Kojima E; Pluda JM; Hui F; Yarchoan R; Mitsuya H
    Antiviral Res; 1995 Oct; 28(2):133-46. PubMed ID: 8585767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lamivudine (3TC) phosphorylation and drug interactions in vitro.
    Kewn S; Veal GJ; Hoggard PG; Barry MG; Back DJ
    Biochem Pharmacol; 1997 Sep; 54(5):589-95. PubMed ID: 9337075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
    Xie H; Voronkov M; Liotta DC; Korba BA; Schinazi RF; Richman DD; Hostetler KY
    Antiviral Res; 1995 Oct; 28(2):113-20. PubMed ID: 8585765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Gao Q; Gu Z; Parniak MA; Cameron J; Cammack N; Boucher C; Wainberg MA
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1390-2. PubMed ID: 8392313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
    Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP.
    Feng JY; Shi J; Schinazi RF; Anderson KS
    FASEB J; 1999 Sep; 13(12):1511-7. PubMed ID: 10463941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.
    Severini A; Liu XY; Wilson JS; Tyrrell DL
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1430-5. PubMed ID: 7492080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
    Arts EJ; Marois JP; Gu Z; Le Grice SF; Wainberg MA
    J Virol; 1996 Feb; 70(2):712-20. PubMed ID: 8551607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
    Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
    J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.
    Geleziunas R; Arts EJ; Boulerice F; Goldman H; Wainberg MA
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1305-12. PubMed ID: 8392310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
    Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
    Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
    Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro.
    Coates JA; Inggall HJ; Pearson BA; Penn CR; Storer R; Williamson C; Cameron JM
    Antiviral Res; 1991 Feb; 15(2):161-8. PubMed ID: 1677557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
    Baba M; Shigeta S; Yuasa S; Takashima H; Sekiya K; Ubasawa M; Tanaka H; Miyasaka T; Walker RT; De Clercq E
    Antimicrob Agents Chemother; 1994 Apr; 38(4):688-92. PubMed ID: 7518216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
    Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential susceptibility of retroviruses to nucleoside analogues.
    Rosenblum LL; Patton G; Grigg AR; Frater AJ; Cain D; Erlwein O; Hill CL; Clarke JR; McClure MO
    Antivir Chem Chemother; 2001 Mar; 12(2):91-7. PubMed ID: 11527046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
    van 't Wout AB; Ran LJ; Nijhuis M; Tijnagel JM; de Groot T; van Leeuwen R; Boucher CA; Schuitemaker H; Schuurman R
    AIDS; 1998 Jul; 12(10):1169-76. PubMed ID: 9677166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.